Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Genmab
Bristol-Myers Squibb
Toray Industries, Inc
NGM Biopharmaceuticals, Inc
Eucure (Beijing) Biopharma Co., Ltd
Immodulon Therapeutics Ltd
Eli Lilly and Company
Seagen Inc.
Eli Lilly and Company